Preliminary results of this ongoing phase 2 trial demonstrated a safe safety profile characterized by aspartate and alanine aminotransferase increases (48%), pyrexia (33%), neutrophil count decrease (30%) and anemia (26%). This evidence concerns the gene GPT and anemia (phenotype).